Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Eiger BioPharmaceuticals, Inc. EIGRQ

Healthcare  —  Biotechnology
8.50 0.00 0.00% as of 1 Oct
Market cap
$2.6M
P/E
0.0×
Cash Flow Champion (3y) Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Eiger BioPharmaceuticals, Inc. (EIGRQ) Business Profile

Updated before January 2025

Company Overview

Eiger BioPharmaceuticals, Inc. (EIGRQ) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare and ultra-rare diseases. Founded in 2008 and headquartered in Palo Alto, California, Eiger has positioned itself as a leader in addressing unmet medical needs in the rare disease space. The company was established with a mission to bring life-changing treatments to patients suffering from conditions that have limited or no therapeutic options.

Eiger’s leadership team is composed of seasoned professionals with extensive experience in the pharmaceutical and biotechnology industries. The company’s CEO, David Cory, has been instrumental in driving Eiger’s strategic vision and operational growth. Under his leadership, Eiger has advanced its pipeline of therapies and established partnerships with key stakeholders in the healthcare ecosystem.

Core Business Segments

Eiger BioPharmaceuticals focuses on the development of therapies for rare diseases, with a particular emphasis on conditions that have high unmet medical needs. The company’s core business segments include:

Hepatitis Delta Virus (HDV) Therapies

Eiger is at the forefront of developing treatments for Hepatitis Delta Virus (HDV), the most severe form of viral hepatitis. Its lead product candidate, Lonafarnib, is an oral therapy designed to inhibit the replication of HDV. Lonafarnib has shown promising results in clinical trials and is a cornerstone of Eiger’s portfolio.

Rare Metabolic Disorders

Eiger is also developing therapies for rare metabolic disorders. One of its key products in this segment is Zokinvy (lonafarnib), which has been approved by the FDA for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) and processing-deficient Progeroid Laminopathies. This approval marked a significant milestone for the company and underscored its commitment to addressing rare diseases.

Pulmonary Arterial Hypertension (PAH)

Eiger is exploring innovative treatments for pulmonary arterial hypertension, a rare and life-threatening condition. The company’s investigational therapies aim to improve patient outcomes and quality of life.

Other Rare Diseases

In addition to its focus on HDV, metabolic disorders, and PAH, Eiger is actively pursuing therapies for other rare diseases. Its pipeline includes multiple product candidates in various stages of development, reflecting its commitment to innovation and patient-centric care.

Business Model

Eiger BioPharmaceuticals operates on a business model that integrates research, development, and commercialization of therapies for rare diseases. The company’s approach is centered on:

  • Pipeline Development: Eiger invests heavily in research and development to advance its pipeline of therapies. The company leverages its expertise in rare diseases to identify and develop innovative treatments.
  • Regulatory Approvals: Eiger works closely with regulatory agencies to secure approvals for its therapies. The company’s success in obtaining FDA approval for Zokinvy demonstrates its ability to navigate the regulatory landscape.
  • Commercialization: Eiger employs a targeted commercialization strategy to bring its therapies to market. The company focuses on building relationships with healthcare providers, payers, and patient advocacy groups to ensure access to its treatments.
  • Partnerships: Eiger collaborates with academic institutions, research organizations, and industry partners to accelerate the development and commercialization of its therapies.

Strategic Direction

Eiger BioPharmaceuticals is committed to advancing its mission of improving the lives of patients with rare diseases. The company’s strategic priorities include:

  • Pipeline Expansion: Eiger aims to expand its pipeline by developing new therapies and exploring additional indications for its existing products.
  • Global Reach: The company is focused on expanding its presence in international markets to reach more patients in need.
  • Sustainability Goals: Eiger is dedicated to sustainability and is working to minimize its environmental impact through responsible business practices.
  • Innovation: Eiger continues to invest in cutting-edge research and development to drive innovation in the rare disease space.

Competitive Landscape

Eiger BioPharmaceuticals operates in a competitive landscape that includes both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Gilead Sciences: A leader in antiviral therapies, Gilead is a major competitor in the HDV space.
  • BioMarin Pharmaceutical: Known for its focus on rare diseases, BioMarin competes with Eiger in the development of therapies for metabolic disorders.
  • Vertex Pharmaceuticals: Vertex is a prominent player in the rare disease market and poses competition to Eiger in certain therapeutic areas.
  • Ultragenyx Pharmaceutical: Ultragenyx specializes in rare and ultra-rare diseases and competes with Eiger in the development of innovative treatments.

Risk Factors

Eiger BioPharmaceuticals faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Regulatory Challenges: The company’s success depends on obtaining regulatory approvals for its therapies, which can be a complex and uncertain process.
  • Market Dependence: Eiger relies heavily on the success of its lead product candidates, such as Lonafarnib, to drive revenue growth.
  • Supply Chain Disruptions: The company’s operations could be affected by disruptions in the supply chain, including shortages of raw materials and manufacturing delays.
  • Competition: Eiger operates in a competitive market, and the success of its therapies depends on their ability to differentiate from competing products.
  • Financial Constraints: As a clinical-stage company, Eiger faces financial risks associated with funding its research and development activities.

Recent Developments

Eiger BioPharmaceuticals has made significant progress in advancing its pipeline and achieving key milestones. Recent developments include:

  • FDA Approval of Zokinvy: The approval of Zokinvy for HGPS and processing-deficient Progeroid Laminopathies marked a major achievement for Eiger.
  • Clinical Trial Advancements: Eiger has reported positive results from clinical trials of Lonafarnib for HDV, demonstrating its potential as a groundbreaking therapy.
  • Partnerships and Collaborations: The company has entered into strategic partnerships to accelerate the development and commercialization of its therapies.
  • Global Developments: Eiger is actively expanding its presence in international markets and exploring opportunities for growth.

Investment Considerations

Investors considering Eiger BioPharmaceuticals should weigh the following factors:

Strengths

  • Focus on Rare Diseases: Eiger’s specialization in rare diseases positions it as a leader in a high-growth market.
  • Innovative Pipeline: The company’s robust pipeline of therapies offers significant growth potential.
  • Regulatory Success: Eiger’s ability to secure FDA approval for Zokinvy demonstrates its expertise in navigating the regulatory landscape.

Risks

  • Financial Uncertainty: As a clinical-stage company, Eiger faces financial risks associated with funding its operations.
  • Market Competition: The company operates in a competitive market, and its success depends on the differentiation of its therapies.
  • Regulatory Challenges: Eiger’s ability to obtain regulatory approvals for its therapies is critical to its success.

Conclusion

Eiger BioPharmaceuticals, Inc. is a pioneering biopharmaceutical company dedicated to addressing unmet medical needs in the rare disease space. With a robust pipeline of innovative therapies, a focus on patient-centric care, and a commitment to sustainability, Eiger is well-positioned for future growth. While the company faces challenges associated with regulatory approvals and market competition, its strengths in innovation and specialization in rare diseases make it a compelling investment opportunity. As Eiger continues to advance its pipeline and expand its global presence, it is poised to make a significant impact on the lives of patients worldwide.